Company
(location)

Type of
financing

Number of
shares,
units
or warrants
(M)

Amount
raised
(M)

Investors; placement agents; details

 

Date

TOTAL: $1,443.01M

Cellectis SA (Paris)

Exercise of warrants

7.4W

$16.5

Cellectis received €13.2M (US$16.5M) through the exercise of about 7.4M warrants of the 12.2M warrants (60.3M) issued in October 2011; an additional 1.5M new shares were issued as a result

11/13/14

Coronado Biosciences Inc. (Burlington, Mass.)

Private placement of restricted common stock

2.17S

$3.5

Coronado raised $3.5M through a private placement of restricted common stock, priced at $1.61 each; DAK Capital, CEO Lindsay Rosenwald, Executive Vice Chairman Michael Weiss and director Malcolm Hoenlein all participated in the financing

11/10/14

Critical Outcome Technologies Inc. (London, Ont.)

Private placement

5.1S

$1.2

Critical Outcome completed a second tranche of its nonbrokered private placement with the issuance of 5.1M shares priced at C23 cents each, for gross proceeds of about C$1.3M (US$1.2M), bringing its total raise to about C$1.8M

11/10/14

Eleven Biotherapeutics Inc. (Cambridge, Mass.)

Private placement of common shares and warrants

1.7S and W for 0.9S

$20

Eleven Biotherapeutics agreed to sell $20M in common shares and warrants to undisclosed investors in a private placement; the company issued approximately 1.7M common shares at $11.47 apiece, and warrants to purchase approximately 900,000 common shares at an exercise price of $15 apiece

11/26/14

Fibrogen Inc. (San Francisco)

Private placement

1.11S

$20

Fibrogen raised $20M through a private placement of 1.11M shares at $18 apiece with Astrazeneca plc; the placement was done concurrently with the company's initial public offering, which raised $145.8M

11/17/14

Galena Biopharma Inc. (Portland, Ore.)

Purchase agreement

N/A

$55

Galena Biopharma executed a purchase agreement for up to $55M with Lincoln Park Capital Fund LLC

11/24/14

Genocea Biosciences Inc. (Cambridge, Mass.)

Loan and security agreement

N/A

$2

Genocea entered a $27M loan and security agreement with Hercules Technology Growth Capital Inc.; the company will use an initial draw of $12M to repay its existing term loan facility and to provide additional working capital for general corporate purposes; the agreement allows Genocea to draw up to an additional $5M at its option through June 30, 2015; two further tranches of $5M each can be drawn down at the company's option on or prior to Dec. 15, 2015, subject to the achievement of certain clinical and corporate milestones; additionally, Genocea entered an equity rights letter agreement with Hercules where they purchased 223,463 shares of the company's common stock at $8.95 each for about $2M

11/24/14

Gtx Inc. (Memphis, Tenn.)

Private placement

64.3S and W for 64.3S

$43.4

Gtx sold 64.3M units for $43.4M to Biotechnology Value Fund LP and other affiliates of BVF Partners LP, certain existing Gtx stockholders and certain members of the Gtx management team and board of directors

11/18/14

Isis Pharmaceuticals Inc. (Carlsbad, Calif.)

Convertible senior notes offering

N/A

$285

Isis plans to offer $425M in convertible senior notes due 2021 in a private placement, with a 30-day option to purchase up to $63.75M in additional convertible notes to cover overallotments;a portion will repurchase up to $140M in convertible senior notes due 2019

11/12/14

Lexicon Pharmaceuticals Inc. (The Woodlands, Texas)

Private offering of convertible senior notes due 2021

N/A

$80

Lexicon began an offering to sell $80M in convertible senior notes due 2021 in a private offering to qualified institutional buyers; initial purchasers will receive an option for $11.2M more of the convertibles

11/21/14

Lexicon Pharmaceuticals Inc. (The Woodlands, Texas)

Private placement

149.3S

$150

Lexicon entered a purchase agreement with Invus LP, Invus CV and Artal International SCA, in which Artal agreed to purchase an aggregate of $150M of shares in a private placement; the agreement was disclosed concurrently with the company's $50M public offering and $80M convertible note offering

11/25/14

Myos Corp. (Cedar Knolls, N.J.)

Registered direct offering

0.194S

$1.81

Myos entered an agreement with selected institutional investors to raise about $1.81M in gross proceeds in a registered direct offering through the sale of 193,865 shares of its common stock at a price of $9.37 per share; investors will also receive: 66-month class C warrants to purchase an aggregate of 145,399 shares of common stock at an exercise price of $12 per share; six-month class D warrants to purchase an aggregate of 193,865 shares of common stock at an exercise price of $9.37 per share; and 84-month class E warrants to purchase an aggregate of 145,399 shares of common stock with an exercise price of $15 per share

11/19/14

Northwest Biotherapeutics Inc. (Bethesda, Md.)

Equity investment and mortgage

N/A

$35

Northwest completed two financings totaling $35M, which includes a $25M equity investment by UK-based C.F. Woodford Equity Income Fund and a $10M mortgage on the company's recently acquired UK facility

11/21/14

Prometic Life Sciences Inc. (Laval, Quebec)

Bought deal financing

13.2S

$25.1

Prometic entered an agreement with underwriters led by Canaccord Genuity Corp., under which they will buy, on a bought-deal basis, 13.2M common shares at $1.90 per share to raise $25.1M; underwriters also have the option to purchase an additional 2M shares

11/20/14

Sinopharm Group Co. (China)

Private placement

199S

$700

Sinopharm is raising $700M through a placement of 199M Hong Kong shares at HK$28.40 (US$3.66) per share, accounting for 20% of the shares in Hong Kong and 7.74% total issued share capital

11/26/14

Xenon Pharmaceuticals Inc. (Burnaby, British Columbia; XENE)

Private placement

0.495S

$4.5

Xenon raised $4.5M by placing 495,000 shares with Genentech Inc. in a private placement done concurrently with the completion of an initial public offering that raised $36M

11/7/14

Notes

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed.

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

N/A = Not applicable; ND = Not disclosed.

This chart includes only biotech companies that develop therapeutics.